Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fimaporfin/gemcitabine - PCI Biotech

X
Drug Profile

Fimaporfin/gemcitabine - PCI Biotech

Alternative Names: Amphinex; Fimaporfin delivered gemcitabine - PCI Biotech; TPCS-2A

Latest Information Update: 30 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PCI Biotech
  • Class Amines; Antineoplastics; Benzenesulfonates; Deoxyribonucleosides; Fluorinated hydrocarbons; Ketones; Porphyrins; Pyrimidine nucleosides; Pyrimidines; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Cholangiocarcinoma

Most Recent Events

  • 24 Jan 2022 PCI Biotech decides to stop the phase II RELEASE trial in Cholangiocarcinoma (Combination therapy, Metastatic disease, Inoperable/Unresectable) in Belgium, Denmark, France, Finland, Germany, Italy, Norway, Poland, Sweden, Spain, South Korea, Taiwan, USA, and Ukraine (IV) due to results from the phase III TOPAZ-1 trial (NCT04099888),
  • 13 Dec 2021 Independent Data Monitoring Committee (IDMC) recommends to continue the phase II RELEASE trial in Cholangiocarcinoma and permitted to continue with up to two fimaChem treatments as stated in the protocol
  • 28 May 2021 Fimaporfin/gemcitabine receives Orphan Drug status for Cholangiocarcinoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy) in South Korea

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top